206 related articles for article (PubMed ID: 16675716)
1. Brief report: effect of intravenous methotrexate dose and infusion rate on neuropsychological function one year after diagnosis of acute lymphoblastic leukemia.
Carey ME; Hockenberry MJ; Moore IM; Hutter JJ; Krull KR; Pasvogel A; Kaemingk KL
J Pediatr Psychol; 2007 Mar; 32(2):189-93. PubMed ID: 16675716
[TBL] [Abstract][Full Text] [Related]
2. Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate.
Spiegler BJ; Kennedy K; Maze R; Greenberg ML; Weitzman S; Hitzler JK; Nathan PC
J Clin Oncol; 2006 Aug; 24(24):3858-64. PubMed ID: 16921038
[TBL] [Abstract][Full Text] [Related]
3. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
Joannon P; Oviedo I; Campbell M; Tordecilla J
Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
[TBL] [Abstract][Full Text] [Related]
4. [Methotrexate-induced interstitial pneumonitis in a child with acute lymphoblastic leukemia].
Tatsumoto C; Kawakami K; Nagayama J; Kawano H
Rinsho Ketsueki; 2004 Oct; 45(10):1100-4. PubMed ID: 15553044
[TBL] [Abstract][Full Text] [Related]
5. [Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia].
Xu WQ; Tang YM; Fang CQ; Song H; Shi SW; Yang SL; Ren DT; Shen HQ; Qian BQ
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):15-8. PubMed ID: 15946502
[TBL] [Abstract][Full Text] [Related]
6. Long-term cognitive outcome, brain computed tomography scan, and magnetic resonance imaging in children cured for acute lymphoblastic leukemia.
Iuvone L; Mariotti P; Colosimo C; Guzzetta F; Ruggiero A; Riccardi R
Cancer; 2002 Dec; 95(12):2562-70. PubMed ID: 12467071
[TBL] [Abstract][Full Text] [Related]
7. Neuropsychological outcome in chemotherapy-only-treated children with acute lymphoblastic leukemia.
Jansen NC; Kingma A; Schuitema A; Bouma A; Veerman AJ; Kamps WA
J Clin Oncol; 2008 Jun; 26(18):3025-30. PubMed ID: 18565888
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of high-dose methotrexate in infants treated for acute lymphoblastic leukemia.
Lönnerholm G; Valsecchi MG; De Lorenzo P; Schrappe M; Hovi L; Campbell M; Mann G; Janka-Schaub G; Li CK; Stary J; Hann I; Pieters R;
Pediatr Blood Cancer; 2009 May; 52(5):596-601. PubMed ID: 19132729
[TBL] [Abstract][Full Text] [Related]
9. [Accidental shortening time of high dose methotrexate infusion: case report and literature review].
Charfi R; Salouage I; Trabelsi S; Zarrouk M; Gaïes E; Jebabli N; Meddeb B; Lakhal M; Klouz A
Ann Biol Clin (Paris); 2013; 71(2):219-22. PubMed ID: 23587592
[TBL] [Abstract][Full Text] [Related]
10. A comparison of neuropsychological and psychosocial functioning after prophylactic treatment for childhood leukemia in monozygotic twins.
Williams J; Berry DH; Caldwell D; Zolten AJ; Spence GT
Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):289-96. PubMed ID: 1456393
[TBL] [Abstract][Full Text] [Related]
11. High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL).
Skärby T; Jönsson P; Hjorth L; Behrentz M; Björk O; Forestier E; Jarfelt M; Lönnerholm G; Höglund P
Cancer Chemother Pharmacol; 2003 Apr; 51(4):311-20. PubMed ID: 12721759
[TBL] [Abstract][Full Text] [Related]
12. [Accretion of bone mass in patients treated for childhood acute lymphoblastic leukemia].
Muszyńska-Rosłan K; Konstantynowicz J; Krawczuk-Rybak M
Pol Merkur Lekarski; 2007 Oct; 23(136):271-5. PubMed ID: 18293849
[TBL] [Abstract][Full Text] [Related]
13. Retrospective study on elimination delay of methotrexate in high-dose therapy of childhood acute lymphoblastic leukemia in China.
Xu W; Tang Y; Song H; Shi S; Yang S
J Pediatr Hematol Oncol; 2007 Oct; 29(10):688-93. PubMed ID: 17921849
[TBL] [Abstract][Full Text] [Related]
14. High-dose methotrexate in childhood all.
Moe PJ; Holen A
Pediatr Hematol Oncol; 2000 Dec; 17(8):615-22. PubMed ID: 11127393
[TBL] [Abstract][Full Text] [Related]
15. Occurrence and impact of unanticipated variation in intravenous methotrexate dosing.
Parshuram CS; Dupuis LL; To T; Weitzman SS; Koren G; Laupacis A
Ann Pharmacother; 2006 May; 40(5):805-11. PubMed ID: 16638922
[TBL] [Abstract][Full Text] [Related]
16. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
[TBL] [Abstract][Full Text] [Related]
17. Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia.
Dervieux T; Hancock ML; Pui CH; Rivera GK; Sandlund JT; Ribeiro RC; Boyett J; Evans WE; Relling MV
Clin Pharmacol Ther; 2003 Jun; 73(6):506-16. PubMed ID: 12811360
[TBL] [Abstract][Full Text] [Related]
18. [Cerebrospinal fluid methotrexate level in children treated with medium-high and high doses of the drug].
Wysocki M; Balcar-Boroń A; Krzyzanowski M; Szadujkis-Szadurski L; Ozyński T; Nowaczyk-Michalak A
Acta Haematol Pol; 1992; 23(3):185-90. PubMed ID: 1492543
[TBL] [Abstract][Full Text] [Related]
19. Daunorubicin-induced cell kill with 1-hour versus 24-hour infusions: a randomized comparison in children with newly diagnosed acute lymphoblastic leukemia.
Escherich G; Göbel U; Jorch N; Spaar HJ; Janka-Schaub GE
Klin Padiatr; 2007; 219(3):134-8. PubMed ID: 17525906
[TBL] [Abstract][Full Text] [Related]
20. Obesity in survivors of childhood acute lymphoblastic leukemia and lymphoma.
Razzouk BI; Rose SR; Hongeng S; Wallace D; Smeltzer MP; Zacher M; Pui CH; Hudson MM
J Clin Oncol; 2007 Apr; 25(10):1183-9. PubMed ID: 17401007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]